FrancophonIA/ELRC3.0 huggingface dataset:
English: The full EPAR for Tybost can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tybost je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Tybost.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tybost.
English: Other information about Tybost
Slovenian: Druge informacije o zdravilu Tybost
English: Tybost was shown to be as effective as ritonavir: around 85% of patients (293 out of 344 patients) given Tybost responded to treatment, compared with around 87% of patients (304 out of 348 patients) given ritonavir.
Slovenian: Zdravilo Tybost se je izkazalo za enako učinkovito kot ritonavir: na zdravljenje se je odzvalo približno 85 % bolnikov (293 od 344 bolnikov), ki so dobivali zdravilo Tybost, in približno 87 % bolnikov (304 od 348 bolnikov), ki so dobivali ritonavir.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Tybost's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tybost večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: A risk management plan has been developed to ensure that Tybost is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Tybost je bil pripravljen načrt obvladovanja tveganj.
English: Treatment should be started by a doctor who is experienced in managing HIV infection.
Slovenian: Zdravljenje mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužb z virusom HIV.
English: What are the risks associated with Tybost?
Slovenian: Kakšna tveganja so povezana z zdravilom Tybost?
English: It is not intended to provide practical advice on how to use Tybost.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What benefits of Tybost have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Tybost izkazalo v študijah?
English: When the enzyme is blocked, the virus cannot reproduce normally, which slows down the spread of infection.
Slovenian: Ko se onemogoči delovanje encima, se virus ne more normalno razmnoževati, zato se upočasni širjenje okužbe.
English: What is Tybost and what is it used for?
Slovenian: Kaj je zdravilo Tybost in za kaj se uporablja?
English: Tybost was compared with another medicine called ritonavir in one main study involving 698 patients infected with HIV-1.
Slovenian: Zdravilo Tybost so primerjali z drugim zdravilom, imenovanim ritonavir, v eni glavni študiji s 698 bolniki, okuženimi z virusom HIV-1.
English: Why is Tybost approved?
Slovenian: Zakaj je bilo zdravilo Tybost odobreno?
English: Tybost must not be taken together with a number of other medicines that affect the way Tybost is broken down or whose action is affected by Tybost: alfuzosin (used to treat an enlarged prostate gland); amiodarone or quinidine (used to correct irregular heartbeat); carbamazepine, phenobarbital, or phenytoin (used to prevent seizures); rifampicin (used to prevent and treat tuberculosis and other infections); dihydroergotamine, ergometrine or ergotamine (used to treat migraine headache); cisapride (used to relieve certain stomach problems); St. John's wort (a herbal remedy used for depression and anxiety); lovastatin or simvastatin (used to lower blood cholesterol); pimozide (used to treat abnormal thoughts or feelings); sildenafil (used to treat pulmonary arterial hypertension); and oral midazolam or triazolam (used to aid sleep or relieve anxiety).
Slovenian: Zdravilo Tybost se ne sme jemati skupaj s številnimi drugimi zdravili, ki vplivajo na način njegove razgradnje ali na delovanje katerih lahko vpliva zdravilo Tybost: alfuzosinom (uporablja se za zdravljenje povečane prostate); amiodaronom ali kinidinom (uporabljata se za zdravljenje nepravilnega srčnega utripa); karbamazepinom, fenobarbitalom ali fenitoinom (uporabljajo se za preprečevanje epileptičnih napadov); rifampicinom (uporablja se za preprečevanje in zdravljenje tuberkuloze in drugih okužb); dihidroergotaminom, ergometrinom ali ergotaminom (uporabljajo se za zdravljenje glavobola zaradi migrene); cisapridom (uporablja se za lajšanje nekaterih želodčnih težav); šentjanževko (zeliščni pripravek, ki se uporablja proti depresiji in tesnobi); lovastatinom ali simvastatinom (uporabljata se za zniževanje holesterola v krvi); pimozidom (uporablja se za zdravljenje nenormalnih misli ali občutkov); sildenafilom (uporablja se za zdravljenje pljučne arterijske hipertenzije); peroralno obliko midazolama ali triazolama (uporabljata se za pomoč pri spanju ali lajšanje tesnobe).
English: The CHMP considered that there were no safety concerns preventing Tybost from being used together with atazanavir or darunavir.
Slovenian: CHMP je menil, da ni nobenih varnostnih zadržkov, zaradi katerih zdravila Tybost ne bi bilo mogoče uporabljati skupaj z atazanavirjem ali darunavirjem.
English: It is used in the treatment of adults infected with HIV-1, a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Uporablja se pri zdravljenju odraslih, okuženih z virusom HIV-1, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tybost, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Tybost vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For more information about treatment with Tybost, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Tybost preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Tybost cobicistat
Slovenian: Tybost kobicistat
English: The main measure of effectiveness was based on the reduction in viral load (the amount of virus found in the blood): patients who attained a viral load of less than 50 HIV-1 RNA copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Slovenian: Glavno merilo učinkovitosti je temeljilo na zmanjšanju virusnega bremena (količine virusa v krvi): veljalo je, da so se na zdravljenje odzvali tisti bolniki, pri katerih se je po 48 tednih zdravljenja virusno breme zmanjšalo na manj kot 50 HIV-1 RNK kopij/ml.
English: Tybost is given together with 300 mg atazanavir once per day or with 800 mg darunavir once per day.
Slovenian: Zdravilo Tybost se daje skupaj s 300 mg atazanavirja enkrat na dan ali z 800 mg darunavirja enkrat na dan. Za več informacij glejte navodilo za uporabo.
English: For practical information about using Tybost, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Tybost naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Tybost is a medicine that contains the active substance cobicistat.
Slovenian: Tybost je zdravilo, ki vsebuje zdravilno učinkovino kobicistat.
English: The most common side effects with Tybost (which may affect more than 1 in 10 people) when given with atazanavir are ocular icterus (yellowing of the whites of the eyes), nausea (feeling sick) and jaundice (yellowing of the skin and eyes).
Slovenian: Najpogostejši neželeni učinki zdravila Tybost (ki lahko prizadenejo več kot 1 osebo od 10) pri sočasni uporabi z atazanavirjem so očesni ikterus (porumenele beločnice), navzea (slabost) in zlatenica (porumenelost kože in oči).
English: Tybost can only be obtained with a prescription.
Slovenian: Izdaja zdravila Tybost je le na recept.
English: The active substance in Tybost, cobicistat, blocks the action of a group of liver enzymes called CYP3A, which are involved in breaking down medicines in the body.
Slovenian: Zdravilna učinkovina v zdravilu Tybost, kobicistat, zavira delovanje skupine jetrnih encimov, imenovanih CYP3A, ki sodelujejo pri razgradnji zdravil v telesu.
English: Studies showed that Tybost was as effective as ritonavir as a booster for atazanavir, and a similar effect is expected for darunavir based on data on the impact of Tybost on the darunavir levels in the body.
Slovenian: Študije so pokazale, da je bilo zdravilo Tybost enako učinkovito kot ritonavir pri krepitvi atazanavirja, glede na podatke o vplivu zdravila Tybost na ravni darunavirja v telesu pa se pričakuje podoben učinek tudi pri darunavirju.
English: Tybost is taken with atazanavir or darunavir, both of which are protease inhibitors: they block an enzyme called protease that is involved in the reproduction of the HIV-1 virus.
Slovenian: Zdravilo Tybost se jemlje skupaj z atazanavirjem ali darunavirjem, ki sta sicer zaviralca proteaze: zavirata delovanje encima, imenovanega proteaza, ki sodeluje pri razmnoževanju virusa HIV-1.
English: For the full list of all side effects reported with Tybost, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tybost, glejte navodilo za uporabo.
English: The study compared these two medicines when used to boost the effects of atazanavir, given in combination with another standard HIV-1 medicine containing emtricitabine and tenofovir.
Slovenian: Omenjeni zdravili so v študiji primerjali, ko so ju uporabili za okrepitev učinkov atazanavirja, ki so ga dajali skupaj z drugim standardnim zdravilom proti virusu HIV-1, ki vsebuje emtricitabin in tenofovir.
English: By blocking CYP3A, Tybost slows down the rate at which atazanavir and darunavir are broken down, thereby prolonging the length of time they act in the body.
Slovenian: Z zaviranjem encimov CYP3A zdravilo Tybost upočasni hitrost razgradnje atazanavirja in darunavirja, s čimer se podaljša čas njunega delovanja v telesu.
English: Tybost does not treat HIV directly but is given to boost the effects of atazanavir or darunavir, which are used with other standard medicines to treat HIV-1.
Slovenian: Zdravilo Tybost ne zdravi neposredno okužbe z virusom HIV, temveč se daje za krepitev učinkov atazanavirja ali darunavirja, ki se uporabljata z drugimi standardnimi zdravili za zdravljenje HIV-1.
English: Treatment with Tybost and atazanavir or darunavir does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS, when combined with other standard HIV-1 medicines.
Slovenian: Zdravljenje z zdravilom Tybost in atazanavirjem ali darunavirjem ne ozdravi okužbe z virusom HIV-1 ali aidsa, vendar lahko v kombinaciji z drugimi standardnimi zdravili proti virusu HIV-1 upočasni slabšanje imunskega sistema in razvoj okužb ter bolezni, povezanih z aidsom.
English: How is Tybost used?
Slovenian: Kako se zdravilo Tybost uporablja?
English: How does Tybost work?
Slovenian: Kako zdravilo Tybost deluje?
English: It usually disappears spontaneously within one week.
Slovenian: Običajno spontano izgine v enem tednu.
English: This summary was last updated in March 2013.
Slovenian: Povzetek je bil nazadnje posodobljen marca 2013.
English: The main measure of effectiveness was the time until the tumours came back or spread (relapse).
Slovenian: Glavno merilo učinkovitosti je bil čas do ponovnega pojava ali razširitve (ponovitve) tumorjev.
English: Canarypox viruses do not spread or multiply in cats or in mammals.
Slovenian: Pox virusi kanarčkov se ne širijo ali množijo v mačkah ali sesalcih.
English: A moderate reaction at the injection site may occur that involves signs of pain when the area is touched, swelling and scratching.
Slovenian: Pojavi se lahko zmerna reakcija na mestu injiciranja, ki vključuje znake bolečine ob dotiku tega mesta, oteklino in srbenje.
English: Oncept IL-2 reduced the risk of relapse in the period from six months after the start of treatment by approximately 56% after one year and 65% after two years.
Slovenian: Zdravilo Oncept IL-2 je zmanjšalo nevarnost ponovitve bolezni v obdobju šestih mesecev po začetku zdravljenja za približno 56 % po enem letu in 65 % po dveh letih.
English: Each dose is divided into five injections (of approximately 0.2 ml each) under the skin around the site of the surgically removed tumour.
Slovenian: Posamezen odmerek se daje s petimi injekcijami (po približno 0,2 ml) pod kožo okoli mesta kirurško odstranjenega tumorja.
English: It is used in combination with surgery and radiotherapy to reduce the risk of and delay the tumour coming back.
Slovenian: Uporablja se v kombinaciji s kirurškim posegom in radioterapijo za zmanjšanje nevarnosti ponovnega pojava bolezni in podaljšanje časa do ponovnega pojava bolezni.
English: A course of treatment consists of six doses of 1 ml, the first four given at intervals of one week, and the last two at two-week intervals.
Slovenian: Zdravljenje je sestavljeno iz šestih odmerkov po 1 ml, pri čemer se prve štiri injicira v enotedenskih presledkih, zadnja dva pa v razmiku dveh tednov.
English: Side effects that may be seen with Oncept IL-2 treatment are short lived apathy (lack of responsiveness) and hyperthermia (increased body temperature above 39.5 °C from the normal value of 38 - 38.5 °C).
Slovenian: Neželena učinka, ki se lahko pojavita pri uporabi zdravila Oncept IL-2, sta prehodna apatija (zmanjšana odzivnost) in hipertermija (povišana telesna temperatura nad 39,5 °C ob normalni vrednosti med 38 in 38,5 °C).
English: The studies showed that in cats treated with Oncept IL-2 the tumours took longer to come back (over 730 days based on the mid value of the range) compared with control cats (287 days).
Slovenian: Študije so pokazale, da so se pri mačkah, zdravljenih z zdravilom Oncept IL-2, tumorji ponovno pojavili kasneje (po več kot 730 dneh glede na srednjo vrednost razpona) kot pri mačkah v kontrolni skupini (po 287 dneh).
English: Treatment with Oncept IL-2 should begin the day before radiotherapy and preferably within one month of the removal of the tumour by surgery.
Slovenian: Zdravljenje z zdravilom Oncept IL-2 je treba začeti en dan pred radioterapijo in po možnosti v enem mesecu po kirurški odstranitvi tumorja.
English: It is available as a lyophilisate (freeze dried pellet) and solvent (water for injections) that are made up into a suspension for injection.
Slovenian: Na voljo je v obliki liofilizata (pelete, posušene v zamrznjenem stanju) in vehikla (vode za injekcije), iz katerih se pripravi suspenzija za injiciranje.
English: The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Slovenian: Za razmerje med koristmi in tveganji glejte modul o znanstveni razpravi v tem povzetku.
English: Oncept IL-2 is used when the size of the tumour is between 2 and 5 cm in diameter and there is no spread of the cancer to other parts of the body.
Slovenian: Zdravilo Oncept IL-2 se uporablja, kadar je premer tumorja od 2 do 5 cm in se rak ni razširil na druge dele telesa.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Onept IL-2 on 3/05/2013.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Oncept IL-2, veljavno po vsej Evropski uniji, odobrila dne 3. maja 2013.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Oncept IL-2 exceed the risks for the approved indication and recommended that Oncept IL-2 be given a marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Oncept IL-2 za odobreno indikacijo večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: Oncept-IL2 is an immunomodulating agent, which means that it affects the activity of the immune system (the body's natural defences).
Slovenian: Zdravilo Oncept IL-2 je imunomodulator, kar pomeni, da vpliva na delovanje imunskega sistema (naravnega obrambnega mehanizma telesa).
English: This is expected to kill the cancer cells.
Slovenian: S tem naj bi uničil rakave celice.
English: The two studies compared a total of 48 cats treated with Oncept IL-2 with 23 control cats that just received surgery and radiotherapy.
Slovenian: V študijah so skupno 48 mačk, zdravljenih z zdravilom Oncept IL-2, primerjali s 23 mačkami v kontrolni skupini, ki so tik pred tem prestale kirurški poseg in radioterapijo.
English: IL-2 works by stimulating some of the specialised cells of the immune system to attack the cancer cells.
Slovenian: IL2 deluje tako, da spodbuja nekatere posebne celice imunskega sistema k napadanju rakavih celic.
English: Oncept IL-2 was studied in two field studies involving 71 cats which had spontaneously developed fibrosarcoma that had not spread to other parts of the body.
Slovenian: Zdravilo Oncept IL-2 so raziskali v dveh terenskih študijah, ki sta vključevali 71 mačk, pri katerih se je spontano razvil fibrosarkom, ki se ni razširil na druge dele telesa.
English: If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Slovenian: V primeru nenamernega zaužitja zdravila se je treba takoj posvetovati z zdravnikom in mu pokazati navodila za uporabo ali ovojnino.
English: Other information about Oncept IL-2:
Slovenian: Druge informacije o zdravilu Oncept IL-2:
English: Oncept IL-2 is used to treat cats with fibrosarcoma, a type of aggressive tumour which affects the soft tissues.
Slovenian: Zdravilo Oncept IL-2 se uporablja za zdravljenje mačk s fibrosarkomom, tj. vrsto agresivnega tumorja, ki prizadene mehka tkiva.
English: What benefit has Oncept IL-2 shown during the studies?
Slovenian: Kakšne koristi je zdravilo Oncept IL-2 izkazalo med študijami?
English: Oncept-IL2 is produced by a method known as ‘recombinant DNA technology': it contains viruses that have received a gene (DNA), which makes them able to produce IL-2.
Slovenian: Zdravilo Oncept IL-2 se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK‟, pri kateri virusi prejmejo gen (DNK), s katerim lahko tvorijo IL-2.
English: The virus allows the production of IL-2 in small amounts and for a prolonged time at the injection site.
Slovenian: Virus omogoča, da se na mestu injiciranja daljši čas tvorijo majhne količine IL-2.
English: What is the risk associated with Oncept IL-2?
Slovenian: Kakšna tveganja so povezana z zdravilom Oncept IL-2?
English: Oncept IL-2 is a veterinary medicine that contains the active substance feline interleukin-2 recombinant canarypox virus (vCP1338).
Slovenian: Oncept IL-2 je zdravilo za uporabo v veterinarski medicini, ki vsebuje zdravilno učinkovino rekombinantni pox virus kanarčkov, ki vsebuje mačji interlevkin-2 (vCP1338).
English: Why has Oncept IL-2 been approved?
Slovenian: Zakaj je bilo zdravilo Oncept IL-2 odobreno?
English: The active substance in Oncept IL-2 is a ‘carrier' canarypox virus that contains the gene to produce the protein feline interleukin-2 (IL-2).
Slovenian: Zdravilna učinkovina v zdravilu Oncept IL-2 je „nosilni‟ pox virus kanarčkov, ki vsebuje gen za tvorjenje beljakovine, imenovane mačji interlevkin-2 (IL-2).
English: How has Oncept IL-2 been studied?
Slovenian: Kako je bilo zdravilo Oncept IL-2 raziskano?
English: Feline interleukin-2 recombinant canary pox virus
Slovenian: rekombinantni pox virus kanarčkov, ki vsebuje mačji interlevkin-2
English: What is Oncept IL-2 used for?
Slovenian: Za kaj se zdravilo Oncept IL-2 uporablja?
English: What is Oncept IL-2?
Slovenian: Kaj je zdravilo Oncept IL-2?
English: How does Oncept IL-2 work?
Slovenian: Kako zdravilo Oncept IL-2 deluje?
English: Avenida Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (España)
Slovenian: Avenida Río de Janeiro, 60 - 66, planta 13 08016 Barcelona (Španija)
English: VIAL/MULTI PACKAGE
Slovenian: VIALA / VEČ-PAKETNI
English: The elimination half-life (t½) is 40-50 minutes.
Slovenian: Razpolovni čas izločanja (t½) je 40-50 minut.
English: STATEMENT OF ACTIVE AND OTHER SUBSTANCES 1 ml contains:
Slovenian: NAVEDBA ZDRAVILNE UČINKOVINE IN DRUGIH SNOVI 1 ml vsebuje:
English: Spontaneous recovery occurs within 3 hours.
Slovenian: Do spontanega prenehanja delovanja pride v 3 urah.
English: After treatment, the animal should not be given water or food before it is able to swallow.
Slovenian: Po zdravljenju se živalim, dokler ne morejo požirati, ne daje vode ali hrane.
English: In a clinical study, the requirement for propofol was reduced by 50%.
Slovenian: V klinični študiji je bila potreba po propofolu zmanjšana za 50%.
English: Shelf life after first opening: 3 months at 25°C.
Slovenian: Rok trajanja po prvem odpiranju: 3 mesece pri 25°C.
English: In case of skin or mucosal contact, wash the exposed skin immediately after exposure with large amounts of water and remove contaminated clothes that are in direct contact with skin.
Slovenian: V primeru stika s kožo ali sluznico izpostavljen del nemudoma sperite z velikimi količinami vode in odstranite umazana oblačila, ki so v neposrednem stiku s kožo.
English: EXPIRY DATE EXP: month/year
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: mesec/leto
English: The mean half-life of elimination of dexmedetomidine increased to 1.6 h and the total exposure (AUC) increased by 50%.
Slovenian: Srednja vrednost razpolovnega časa izločanja deksmedetomidina se je povečala na 1,6 h, skupna izpostavljenost (AUC) pa za 50%.
English: However this duration is dependent on a number of variables and further analgesia should be administered in accordance with clinical judgement.
Slovenian: Njeno trajanje je odvisno od številnih dejavnikov, zato je treba nadaljnjo analgezijo dajati glede na klinično presojo.
English: The bioavailability of dexmedetomidine is 60% and the apparent volume of distribution (Vd) is 0.9 L/kg.
Slovenian: Biološka razpoložljivost deksmedetomidina je 60-odstotna in navidezni volumen porazdelitve (Vd) je 0,9 L/kg.
English: The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.
Slovenian: Uporaba deksmedetomidina pri kužkih mlajših od 16 tednov in mačkah mlajših od 12 tednov ni bila preučena.
English: Respiratory and haemodynamic symptoms should be treated symptomatically.
Slovenian: Dihalne in hemodinamične simptome je potrebno zdraviti simptomatično.
English: ADVICE ON CORRECT ADMINISTRATION It is recommended that animals are fasted for 12 hours prior to administration.
Slovenian: NASVET O PRAVILNI UPORABI ZDRAVILA Priporočeno je, da živali postijo 12 ur pred uporabo zdravila.
English: Do not use after the expiry date stated on the label and carton after EXP.
Slovenian: Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenem na nalepki in škatli po EXP.
English: The Marketing Authorisation Holder must ensure that the system of pharmacovigilance, as described in Part 1 of the marketing authorisation application, is in place and functioning before and whilst the veterinary medicinal product is on the market.
Slovenian: Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance, kot je opisan v delu I vloge za pridobitev dovoljenja za promet, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.
English: For information on target animal safety in cases of overdosing, see section 4.10.Overdose
Slovenian: Za informacije o varnosti v primeru prevelikega odmerjanja pri ciljnih živalih glejte 4.10, Preveliko odmerjanje.
English: Metabolites are excreted mainly in the urine (51% of the dose), and to a lesser extent in the faeces.
Slovenian: Presnovki se izločajo večinoma z urinom (51% odmerka) in v manjši meri z blatom.